Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space (SCS™) Drug Administration
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, which develops drug therapies for eye diseases, announces completion of Phase 2 clinical trial enrollment for treatment of macular edema associated with non-infectious uveitis.
